- EIA reagents and devices play a crucial role in detecting antibodies or antigens in samples, making them essential tools in disease surveillance, clinical diagnostics, pharmaceutical research, and food safety testing. Their non-radioactive nature and high throughput capabilities continue to make them the preferred choice in modern laboratories.
- The demand for EIA-based diagnostics is being bolstered by the increasing burden of diseases such as cancer, HIV, hepatitis, and autoimmune disorders, alongside the growing focus on preventive healthcare and population screening programs.
- The U.S. dominates the Immunoassay Reagents and Devices market with the largest revenue share of 38.24% in 2025, owing to advanced healthcare infrastructure, rising healthcare expenditure, early adoption of novel diagnostic technologies, and the presence of leading market players in the region. The U.S. is particularly witnessing substantial growth in EIA applications within hospital labs and academic institutions, driven by innovations in multiplex assays and lab automation.
- Canada is projected to be the fastest-growing country in the Immunoassay Reagents and Devices market during the forecast period, supported by increasing investments in healthcare infrastructure, growing awareness about early disease detection, and a rising patient population.
- The Enzyme Immunoassays segment is expected to dominate the Immunoassay Reagents and Devices market with a market share of 46.1% in 2025, driven by its widespread use in diagnostics due to high sensitivity, specificity, and cost-effectiveness.
